Puma Biotechnology reported $89.06M in Debt for its fiscal quarter ending in June of 2024.





Debt Change Date
Agios Pharmaceuticals USD 31.17M 4.57M Jun/2026
Alnylam Pharmaceuticals USD 2.48B 1.21B Sep/2026
Amgen USD 57.3B 19M Jun/2026
Biogen USD 7.69B 398.3M Sep/2026
BioMarin Pharmaceutical USD 4.19B 11.99M Sep/2026
Daiichi Sankyo JPY 500.48B 200B Jun/2026
Exelixis USD 162.2M 3.73M Sep/2026
Gilead Sciences USD 26.25B 4.07B Jun/2026
Glaxosmithkline GBP 23.7B 4.65B Sep/2026
Incyte USD 38.27M 1.16M Jun/2026
MacroGenics USD 35.09M 1.42M Jun/2026
Moderna USD 1.29B 11M Jun/2026
Novartis USD 49.01B 2.02B Jun/2026
Pfizer USD 62.67B 523M Sep/2026
PTC Therapeutics USD 2.84B 2.15B Sep/2026
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Regeneron Pharmaceuticals USD 2.71B 400K Jun/2026
Roche Holding CHF 33.03B 1.41B Jun/2025
Sangamo BioSciences USD 0 0 Jun/2022
Sarepta Therapeutics USD 857.36M 188.48M Sep/2026
Takeda JPY 4.58T 364.32B Sep/2026
TG Therapeutics USD 754.37M 68K Sep/2026
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Vanda Pharmaceuticals USD 4.96M 4.96M Dec/2024
Vertex Pharmaceuticals USD 6.48B 4.5B Sep/2026